| 陈春燕,单慧亭,赵海霞,丁楠,熊代琴.莫西沙星110例不良反应及其神经/精神毒性的危险因素分析[J].中国药事,2021,35(4):456-461 |
| 莫西沙星110例不良反应及其神经/精神毒性的危险因素分析 |
| Analysis of 110 Cases of Adverse Reactions and Risk Factors Induced by Moxifloxacin |
| |
| DOI：10.16153/j.1002-7777.2021.04.014 |
| 中文关键词: 莫西沙星 药物不良反应 危险因素 |
| 英文关键词: moxifloxacin adverse drug reaction risk factors |
| 基金项目:新疆维吾尔自治区药学会科研基金(编号 YXH201803)；新疆医科大学第一附属医院管理课题(编号 2016GL10)； |
|
| 摘要点击次数: 527 |
| 全文下载次数: 4 |
| 中文摘要: |
| 目的：分析莫西沙星药物不良反应(Adverse Drug Reaction，ADR)发生的规律及特点，并对其神经/精神毒性进行危险因素分析，为临床安全用药提供参考。方法：回顾性分析2018年1月至2019年12 月新疆医科大学第一附属医院上报的全部莫西沙星ADR，并对其神经/精神毒性进行单因素及多因素 Logistic回归分析。结果：收集的110例发生ADR的患者年龄分布集中在60岁以上，性别无显著性差异。 患者的原发疾病以呼吸系统疾病为主。在110例中有3例口服给药，其余均采用静脉滴注给药。ADR多累及皮肤及神经/精神系统，且神经/精神系统ADR的发生与患者的年龄(≥60岁)、合并慢性基础疾病和白蛋白水平相关。110例ADR的发生时间多为用药后7天内，转归时间多为24小时以内。所有患者经停药或对症治疗后均好转或治愈。结论：应加强临床使用莫西沙星的规范性，老年、合并慢性病、血浆白蛋白低的患者更易发生神经/精神系统ADR，需提高监测力度。 |
| 英文摘要: |
| Objective: To analyze the characteristics of adverse drug reaction (ADR) of moxifloxacin, and to analyze the risk factors of its neurological/psychotoxicity, so as to provide references for the clinical safety of medication. Methods: All moxifloxacin ADRs reported from the First Affiliated Hospital of Xinjiang Medical University from January 2018 to December 2019 were retrospectively analyzed and subjected to univariate and multifactorial logistic regression analysis for neuro/psychotoxicity. Results: The age distribution of the 110 patients with ADR was concentrated over 60 years old, with no significant differences by gender. The primary diseases of the patients were predominantly respiratory diseases. Three of the 110 cases were administered orally, and the rest of the ADRs occurred in patients with intravenous preparations. ADRs mostly involved the skin and neurological/psychiatric system, and the occurrence of neurological/psychiatric ADRs was correlated with the patient's age (≥60 years), coexistent chronic underlying diseases and albumin levels. 110 ADRs occurred mostly within 7 days after administration and disappeared within 24 hours. All patients recovered or were cured after drugdiscontinuation or symptomatic treatment. Conclusion: The standardization of clinical use of moxifloxacin should be strengthened. Senior patients with, combined chronic diseases and low plasma albumin are more likely to have neurological/psychiatric ADRs and need to be monitored more cautiously. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |